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ABSTRACT 
Objective: The role of vitamin D in the etiopathogenesis of fibromyalgia and non-specific musculoskeletal 
pain is controversial. In our study, we aimed to investigate the effect of vitamin D therapy on quality of life 
in patients with fibromyalgia. 
Materials and Methods: Seventy patients diagnosed with fibromyalgia and 65 age- and sex-matched controls 
were included in the study. Patients were grouped as deficient (<20 ng/mL), inadequate (20-30 ng/mL), and 
sufficient (>30 ng/mL) according to the levels of vitamin D. Vitamin D replacement was performed for pa-
tients with deficiencies and inadequacies. Before and after vitamin D therapy, patients filled in the assessment 
tools, fibromyalgia impact questionnaire (FIQ), Arizona sexual experience scale (ASEX), Beck depression 
inventory (BDI), visual analog scale (VAS), and short form-36 (SF-36).
Results: Vitamin D deficiencies and inadequacies were observed in 60% of the patients (n=42). Among 
patients with low and normal levels of vitamin D, no statistically significant difference was observed in their 
values. In scales examined after vitamin D replacement therapy, statistically significant differences were ob-
served in the FIQ, BDI, VAS, and SF-36 compared with pre-treatment. 
Conclusion: Vitamin D deficiency seems to be linked to the pathogenesis of fibromyalgia. Vitamin D supple-
mentation may improve the quality of life in patients with fibromyalgia.
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ÖZ 
Amaç: D vitamininin fibromiyalji ve nonspesifik kas-iskelet sistemi ağrılarının etyopatogenezindeki rolü tartışmalıdır. 
Çalışmamızda fibromiyalji hastalarında D vitamini tedavisinin yaşam kalitesi üzerine etkisini araştırmayı amaçladık. 
Gereç ve Yöntem: Çalışmaya fibromiyalji tanısı konulan 70 hasta ve yaş-cinsiyet olarak benzer 65 kişi kontrol 
grubu olarak dahil edildi. D vitamini düzeylerine göre hastalar, eksiklik (<20 ng/mL), yetersizlik (20-30 ng/mL) 
ve yeterli (> 30 ng/mL) olarak gruplandırıldı. Eksiklik ve yetersizlik saptanan hastalar için D vitamini replasmanı 
yapıldı. D vitamini tedavisinden önce ve sonra, hastalar yaşam kalitesi formları olan fibromiyalji etkilenme an-
keti (FEA), Arizona cinsel yaşantılar ölçeği (ACYÖ), Beck depresyon ölçeği (BDÖ), Vizüel Analog skala (VAS) 
and Kısa form-36 (KF-36) ile değerlendirildi.
Bulgular: D vitamini eksikliği ve yetersizliği hastaların % 60’ında (n=42) gözlendi. D vitamini düşük ve normal 
hastalar arasında yaşam kalitesi açısından istatistiksel fark saptanmadı. D vitamini replasman tedavisinden sonra 
yapılan incelemelerde FEA, BDÖ, VAS ’ya göre ağrı skoru ve KF-36’ da tedavi öncesi ile karşılaştırıldığında 
istatistiksel olarak anlamlı farklılıklar gözlendi.
Sonuç: D vitamini eksikliği fibromyalji patogeneziyle bağlantılı görünmektedir. Fibromyalji hastalarında D vita-
min replasmanı yapmak hayat kalitesini yükseltebilir.
Anahtar Kelimeler: Depresyon, fibromyalji, hayat kalitesi, D vitamini, yaygın ağrı
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Introduction
Fibromyalgia syndrome (FMS) is a non-inflammatory disease with widespread musculoskeletal 
pains, fatigue, and susceptibilities, the cause of which is not fully understood [1]. It is a syndrome 
accompanied by many systemic disorders and is observed in all ages, genders, and races. It is 10 
times more frequent in women [2]. Its prevalence increases with age but is most commonly seen 
between the ages of 20 and 55 years [3]. Although symptoms concerning many systems may be 
observed, the most disturbing symptom is widespread pain. This is an important issue not only 
for the patient but also for the physician. Unfortunately, there is no known effective therapy of 
FMS. FMS is not a life-threatening disease; however, it can lead to serious health expenses owing 
to the difficulties encountered in its therapy [4].
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The symptoms of FMS are similar to symptoms 
observed in vitamin D deficiency. Recently, re-
searchers have been curious about this issue 
and have conducted a number of studies [5-
9]. While there were factors that could cause 
confusion such as methodological differences 
and heterogeneous patient populations in these 
studies, vitamin D deficiency was reported in a 
considerable proportion of patients with FMS 
in almost every study. Despite this fact, the re-
lationship between FMS and serum vitamin D 
levels is controversial, an important finding. Pa-
tients’ pains can be reduced and thus the quality 
of life increased with an inexpensive therapeu-
tic method such as vitamin D replacement. In 
a placebo-controlled study carried out on this 
topic, vitamin D replacement was found to be 
ineffective [9]. However, the number of patients 
was insufficient in this study. Additionally, all of 
the participants did not continue with the afore-
mentioned study. In this prospective study, the 
aim was to assess the effect of vitamin D re-
placement on clinical symptoms and disease as-
sociated scores in patients with FMS who were 
observed to have vitamin D deficiency. 
Materials and Methods
Patients and assessment
Seventy female premenopausal patients who 
were diagnosed with FMS according to the 2010 
FMS classification criteria set and who volun-
teered to participate in the study and 65 healthy 
age- and sex-matched controls were included 
in this prospective study [10]. Patients who 
had additional diseases and conditions including 
obesity, smoking, alcohol use history, osteopo-
rosis, and osteoarthritis as well as those with a 
history of drug use that may affect the calcium 
metabolism currently or prior were excluded 
from the study. Blood samples were taken from 
patients in the month of August during which 
the level of vitamin D is the highest. The serum 
25-OH vitamin D level was measured by using 
an enzyme-linked immunosorbent assay (ELISA) 
method. A serum vitamin D level of ≤20 ng/mL 
was identified as vitamin D deficiency, a serum 
level of 21-29 ng/mL was identified as vitamin D 
inadequacy, and a serum level of ≥30 ng/mL was 
identified as normal. 
Female patients in the postmenopausal or 
climacteric period were not included in the 
study. The aim here was to reduce the effect 
of hormonal changes and the effect of osteo-
porosis which frequently accompanies the 
postmenopausal period and thus may affect 
pain. All patients and healthy volunteers were 
informed about the study and informed consent 
was obtained. Before vitamin D replacement, 
the patients were assessed using the following 
scales: fibromyalgia impact questionnaire (FIQ), 
short form-36 (SF-36), visual analog scale (VAS), 
Arizona sexual life questionnaire (ASEX), and 
Beck depression scale. Patients with vitamin D 
deficiency and inadequacy were given a weekly 
dose 50,000 IU vitamin D (Devit-3; Deva) for 
12 weeks orally. At the beginning of the fourth 
month after the initiation of therapy, control 
serum vitamin D levels were measured. It was 
observed that the vitamin D levels of all patients 
returned to normal (≥30 ng/mL). After thera-
py, scoring that was performed before therapy 
was repeated. Vitamin D levels of the patients 
before and after replacement were compared. 
The local ethics committee approval was ob-
tained for the study.
Assessment tools 
Sociodemographic information form
This was developed by researchers and it re-
corded the patient’s age, gender, educational 
level, socioeconomic status, place of residence, 
marital status, and duration of illness.
Fibromyalgia impact questionnaire
This was used to assess the current health status 
of patients with fibromyalgia. Physical function-
ing, work status, depression, anxiety, morning 
tiredness, stiffness, pain, fatigue, and well-being 
over the past week were measured [11]. Its ad-
aptation, reliability, and validity studies were per-
formed by Ediz et al. [12] for Turkey. 
Beck depression inventory (BDI)
It was used to determine the risk of depression 
in the test subject and to measure the level of 
depressive symptoms and the change in severity. 
It was developed by Beck et al. [13]. Its adap-
tation, reliability, and validity studies were per-
formed by Hisli [14] for Turkey. 
Arizona sexual life
Arizona sexual experience scale, which was de-
veloped by McGahuey et al. [15] and the validity 
and reliability studies of which were carried out 
by Soykan [16] in Turkey, was used. In the validity 
and reliability study in Turkey, it was observed that 
the internal consistency and reliability of the scale 
was high with 0.89-0.90 Cronbach’s values and 
as such valid in establishing the sexual dysfunc-
tion. The scale with separate forms for females 
and males was filled in by the patients, and there 
was no need for special training for its interpreta-
tion. The score range of the six-point Likert-type 
scale consisting of five items was 5-30, an increase 
in the total score indicates sexual dysfunction. 
According to Soykan, scale score of ≥11 is the 
breaking point for sexual dysfunction.
Visual Analog Scale
This is a scale that measures the severity of pain. 
VAS is a continuous scale, usually 10 cm (100 
mm) in length, and the score is determined by 
measuring the distance and consists of 3 parts 
(0-30 mm: mild, 40-60 mm: moderate, 70-100 
mm: severe). The scale is adapted to Turkish 
norms and is used in numerous studies measur-
ing pain [17].
SF-36
This is a developed scale for the measurement 
of quality of life. Its Turkish validity and reliability 
studies were performed [18].
Statistical analysis
The statistical analysis of the study data was 
conducted using the Statistical Package for So-
cial Sciences version 13.0 (SPSS Inc.; Chicago, 
IL, USA). Descriptive statistics are presented as 
frequency, percentage, mean, and standard de-
viation. A non-parametric test, one-sample Kol-
mogorov-Smirnov test was used to determine 
whether results from study groups conformed 
to normal distribution. For the analysis of dif-
ferences in continuous variables between two 
groups, the Mann-Whitney U test was used in 
cases where the data distribution was abnormal 
and Student’s t-test was used in cases where the 
data distribution resembled normal distribution. 
A p value less than 0.05 was considered statisti-
cally significant.
Results
In the study, the average age of the patients with 
fibromyalgia was 38.7±5.2 years. Among these 
patients, 95.7 % of them (n=67) were married, 
and 94.3% of them (n=66) had at least one 
child. The level of vitamin D was observed to be 
below 30 ng/mL in 60% of the patients (n=42) 
and in 50.7% of controls (n=33). Biochemical 
and demographic parameters of patients with 
FMS and controls are listed in Table 1. 
Among patients with low and normal levels of 
vitamin D, no statistically significant difference 
was observed in their values in the FIQ, BDI, 
VAS, and ASEX (Table 2). In scales examined af-
ter vitamin D replacement therapy for patients, 
statistically significant differences were observed 
in the FIQ, BDI, and pain scale (VAS) compared 
to pre-treatment (p values, respectively, 0.001, 
0.001, 0.001). After vitamin D therapy, no sig-
nificant difference was observed in the fields of 
ASEX and sleep scores (VAS) (p values, respec-
tively, 0.176, 0.317) (Table 3).
There were no significant difference in patients’ 
quality of life forms between the normal vita-
min D group compared and the low vitamin 
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D group (Table 2). After vitamin D therapy, 
statistically significant improvements were ob-
served in physical function, physical role limita-
tions, emotional role limitations, social function, 
mental health, vitality, and general health fields 
in patients’ quality of life forms (SF-36). No sig-
nificant difference was observed in bodily pain 
levels before and after therapy (Table 3). 
Discussion
Fibromyalgia syndrome has gained more 
importance in recent years due to the fact 
that its etiology has not been illuminated and 
that patients are not totally satisfied with 
the current therapeutic approaches [19]. Al-
though the pain observed in FMS is generally 
described by being burning, gnawing, throb-
bing, and sharp, sometimes patients cannot 
describe the character of the pain. The pain 
and the perception of pain observed in FMS 
have several features [20]. The severity of the 
pain may indicate variability and fluctuations. 
The pain threshold is low and normally pain 
may occur even against a non-painful stimu-
lus. The level of pain experienced is greater 
than is expected from the painful stimulus. 
The pain lasts longer than expected, and it is 
commonly felt without indicating anatomical 
spread. The pain threshold value of patients 
with FMS is lower compared to healthy peo-
ple [21]. Patients’ quality of life is severely 
impaired because of the widespread pain, 
and as a result, they lead isolated lives. The 
time that the patient keeps for himself/her-
self and his/her family decreases. This causes 
unhappiness within the family. They become 
apathetic and anhedonic and enter into a vi-
cious circle. Considering that the prevalence 
in adult society is 2%-4%, it should be consid-
ered as a major health problem for people 
and society. 
There are many studies carried out to de-
scribe the etiopathogenesis of FMS. The aim 
of these studies is to open the door to target-
ed therapies for FMS’s etiopathogenesis. More 
than one cause plays a role in FMS’s possible 
etiopathogenesis. One of them may also be 
the deficiency in serum vitamin D. Likewise 
1.25(OH)D (active vitamin D) functions in 
around 30 tissues and organs in the cell nu-
cleus and cell membrane; the musculoskeletal 
system being one of them [22]. Therefore, 
vitamin D is important for the normal devel-
opment and function of the musculoskeletal 
system. Bone and muscle pains are the well-
known symptoms of vitamin D deficiency, and 
it is documented to be seen without osteoma-
lacia’s biochemical changes [23].
In the study, it was observed that vitamin D 
replacement had positive effects on scores 
associated with quality of life in patients with 
FMS. However, no significant improvement 
was observed in bodily pain levels after ther-
apy. There are also some studies that have 
not found changes in body pain [24, 25]. 
Even though vitamin D deficiency does not 
play a role in the etiopathogenesis of FMS, 
the positive effect seen with vitamin D re-
placement is important in terms of increas-
ing a patient’s quality of life and providing an 
increase in mobilization. Increasing vitamin 
D deficiency along with the increased im-
mobilization, depression, and consequently 
reduced exposure to the sun in FMS is the 
result of a vicious circle. We believe that vi-
tamin D replacement will contribute to the 
breaking of this vicious circle in patients with 
vitamin D deficiency. 
The relationship between FMS and serum vi-
tamin D levels has yet to be clearly illuminated. 
Is vitamin D deficiency the cause or the result 
of FMS? This subject is the point of concern 
among researchers. In analogy to our study, 
Table 2. Scores of FIQ, BDI, VAS, ASEX, sleep VAS, and SF-36 according to vitamin D levels
 Patients with low vit. D Patients with normal vit. D  
Parameter (n=42) (n=28) p
FIQ 61.2±13.5 61.9±15 NS
BDI 15.6±10 18.3±11 NS
VAS 84.4±12.3 85±13 NS
ASEX 18.2±5.2 18.7±6 NS
Sleep scale (VAS) 4.9±2 5.1±1.6 NS
SF-36
1. Physical function 19.7±3.9 20.5±4.4 NS
2. Role physical 5±1.3 4.9±1.1 NS
3. Role emotional 3.7±1 3.6±0.9 NS
4. Bodily pain 5.2±1.3 5.3±1.3 NS
5. Social function 6.7±2.2 5.9±1.5 NS
6. Mental health 19.2±5 17.7±4.8 NS
7. Vitality 13.1±3.2 12.4±3.9 NS
8. General health 11.3±4 11.2±4.1 NS
FIQ: fibromyalgia impact questionnaire; BDI: Beck depression inventory; VAS: visual analog scale; ASEX: Arizona sexual 
experience scale
VAS: 0-30: mild, 40-60: moderate, 70-100: severe; BDI: 0-9: normal, 10-16: mild, 17-29: moderate, 30-63: severe; FIQ: 
0-39: mild, 39-59: moderate, 59-100: severe.
Values are presented as mean±standard deviation.
p<0.05 is significant, NS: nonsignificant
Table 1. Demographic and laboratory data of study groups
Parameter Patient (n=70) Control (n=65)
Age (y) 38.74±5.2 38.03±4.8
Disease duration (y) 5.96±4.6
Number of  births 2.01±0.9 1.93±0.5
Number of  children 1.97±0.8 1.85±0.6
Hemoglobin (g/dL) (12-16 g/dL) 12.9±0.7 12.6±0.6
Calcium (mg/dL) (8.8-10.6 mg/dL) 9.3±0.4 9.4±0.3
Phosphorus (mg/dL) (2.5-4.5 mg/dL) 3.4±0.4 3.4±0.4
Alkaline phosphatase (U/L) (30-120 U/L) 72.5±19.8 74.04±13.6
Parathyroid hormone (ng/L) (12-65 ng/L) 53.4±18.4 41.8±12.2
Vitamin D, n (%) >30 ng/mL 28 (40%) 32 (49.3%)
Values are presented as mean±standard deviation.
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the number of studies in the literature is lim-
ited in which patients are assessed before and 
after vitamin D replacement. In a randomized 
controlled study carried out by Warner et al. 
[9], it was reported that vitamin D was not 
associated with the pain in patients with wide-
spread pain syndrome and that no response 
was received with vitamin D replacement. 
Vitamin D replacement was performed in a 
study in which 30 patients with FMS whose 
vitamin D levels were below 32 ng/mL were 
included. A significant improvement was ob-
served in patients’ VAS pain values when the 
therapy was given. It was emphasized that op-
timizing the vitamin D level in patients with 
FMS would make positive contributions to 
the perception of pain [26]. In a meta-analysis 
consisting of 12 studies and 1,854 patients, it 
was stated that vitamin D and chronic wide-
spread pain syndrome were associated. In this 
meta-analysis, the use of low values such as 
8-10 ng/m: as a diagnostic threshold value in 
widespread pain syndrome instead of 20 ng/
mL of hypovitaminosis physiological value was 
emphasized to be better [27].
As a result, in the study done, it was observed 
that vitamin D deficiency was frequently ob-
served in patients with FMS, and an improve-
ment was observed with vitamin D therapy. 
However, a higher reduction rates in the FIQ 
score and BDI score have been suggested as 
clinically significant by some authors [28]. In 
a recent study by Yilmaz et al. [29] including 
patients with chronic nonspecific widespread 
musculoskeletal pain, it was reported that re-
placement of vitamin D improved the quality 
of life (SF-36). In another study, there were 
no correlations found between vitamin D 
and health status [30]. Assessment tools for 
determining the fibromyalgia are patient-
dependent, and some environmental factors 
and personal mood at that time may affect 
the questionnaire. There is no quantitative 
method. The fact that it was not placebo-con-
trolled is another shortcoming of this study. 
However, the fact that patients with factors 
that would affect the vitamin D level and the 
situations that caused chronic pain were ex-
cluded strengthens the study. 
Vitamin D deficiency may be a factor in-
volved in the pathogenesis of FMS. It seems 
to be associated with the pathogenesis in 
these patients. In addition, serum vitamin D 
levels should be checked as a general health 
problem and patients should be supported 
where necessary. Long-term randomized, 
placebo-controlled prospective studies with 
larger populations are required for the clari-
fication of the relationship between FMS and 
vitamin D.
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